Last $5.11 USD
Change Today -0.05 / -0.97%
Volume 2.6K
SKBI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

skystar bio-pharmaceutical (SKBI) Snapshot

Open
$5.10
Previous Close
$5.16
Day High
$5.15
Day Low
$5.10
52 Week High
07/3/14 - $8.22
52 Week Low
08/1/13 - $1.49
Market Cap
38.9M
Average Volume 10 Days
17.9K
EPS TTM
$1.42
Shares Outstanding
7.6M
EX-Date
--
P/E TM
3.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYSTAR BIO-PHARMACEUTICAL (SKBI)

Related News

No related news articles were found.

skystar bio-pharmaceutical (SKBI) Related Businessweek News

No Related Businessweek News Found

skystar bio-pharmaceutical (SKBI) Details

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People’s Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi’an, the People’s Republic of China.

skystar bio-pharmaceutical (SKBI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $121.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2013.

skystar bio-pharmaceutical (SKBI) Key Developments

Skystar Bio Pharmaceutical Company Approves and Adopts Amendment to the Company's Bylaws

The Board of the Skystar Bio Pharmaceutical Company approved and adopted an amendment to the company's bylaws, as currently in effect (the 'Bylaws'), with respect to the corporate seal of the company, which the effective date of such amendment of the date of the adoption, with the effective date of July 16, 2014. The company filed the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock with the Secretary of State of the State of Nevada, establishing and designating the Series C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $1,000. The Series C Preferred Stock is not redeemable and does not have any liquidation preference. No dividends will be paid on shares of Series C preferred stock. Except as required by law, holders of the Series C Preferred Stock do not have rights to vote on any matters, questions or proceedings, including the election of directors. Subject to certain ownership limitations as described below, the Series C Preferred Stock is convertible at any time at the option of the holder into shares of common stock at a conversion ratio determined by dividing the stated value of the Series C Preferred Stock (or $1,000) by a conversion price of $5.06 per share. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. Subject to limited exceptions, a holder of shares of Series C Preferred Stock will not have the right to convert any portion of its Series C Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to its conversion.

Skystar Bio Pharmaceutical Mulls Acquisitions

Skystar Bio Pharmaceutical Company (NasdaqCM:SKBI) is seeking acquisitions. Skystar Bio Pharmaceutical is planning to raise $5 million from registered direct offering and plans to use part of proceeds for acquisitions too. Skystar Bio Pharmaceutical said, "The Company shall use a portion of the proceeds of the offering for acquisitions, licenses of new vaccine and aquaculture products, research & development and other general corporate purposes."

Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China

Skystar Bio-Pharmaceutical Company announced the launch of a new product in China -- bovine immunoglobulin G (IgG) kits targeting China's domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry. Skystar's bovine immunoglobulin G (IgG) kits are comprised of a proprietary formula of vitamin supplements including B1, B2, B6, and niacin in combination with ATP, immune boosting antigen specific transfer factor molecules and five different immunoglobulin (IgG) G antibodies for the prevention and treatment of commonly occurring diseases found in pig farming, including blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKBI:US $5.11 USD -0.05

SKBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Animal Husbandry Industry Co Ltd CNY14.32 CNY -0.18
Guangdong VTR Bio-Tech Co Ltd CNY42.69 CNY 0.00
Inner Mongolia Jinyu Group Ltd CNY31.40 CNY -0.24
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd CNY9.94 CNY 0.00
View Industry Companies
 

Industry Analysis

SKBI

Industry Average

Valuation SKBI Industry Range
Price/Earnings 3.7x
Price/Sales 0.9x
Price/Book 0.4x
Price/Cash Flow 3.6x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYSTAR BIO-PHARMACEUTICAL, please visit www.skystarbio-pharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.